VanEck Biotech ETF (NASDAQ:BBH – Get Free Report)’s share price reached a new 52-week high during trading on Wednesday. The stock traded as high as $254.75 and last traded at $252.9560, with a volume of 14,100 shares. The stock had previously closed at $249.80.
VanEck Biotech ETF Trading Up 1.4%
The company has a fifty day moving average of $239.77 and a two-hundred day moving average of $205.82.
Hedge Funds Weigh In On VanEck Biotech ETF
A number of large investors have recently bought and sold shares of the company. Kestra Advisory Services LLC lifted its stake in shares of VanEck Biotech ETF by 3.0% in the 1st quarter. Kestra Advisory Services LLC now owns 3,405 shares of the company’s stock worth $640,000 after acquiring an additional 98 shares during the period. Janney Montgomery Scott LLC increased its stake in shares of VanEck Biotech ETF by 3.4% during the first quarter. Janney Montgomery Scott LLC now owns 3,040 shares of the company’s stock worth $572,000 after acquiring an additional 100 shares during the period. Coastline Trust Co acquired a new position in shares of VanEck Biotech ETF during the third quarter worth about $46,000. CoreCap Advisors LLC purchased a new position in VanEck Biotech ETF during the third quarter worth about $46,000. Finally, Manchester Capital Management LLC purchased a new position in VanEck Biotech ETF during the third quarter worth about $74,000. Hedge funds and other institutional investors own 32.05% of the company’s stock.
About VanEck Biotech ETF
The BIOTECH HOLDING COMPANY DEPOSITARY RECEIPTS or HOLDRS TRUST was formed under the depositary trust agreement, among The Bank of New York, as trustee, Merrill Lynch, Pierce, Fenner & Smith Incorporated, other depositors and the owners of the Biotech HOLDRS. The trust currently holds shares of common stock or American depositary shares issued by a group of companies that were, at the time of the initial offering, generally considered to be involved in various segments of thebiotechnology industry.
Read More
- Five stocks we like better than VanEck Biotech ETF
- Why Tesla’s Upside Is About More Than a SpaceX Merger
- Amkor’s Mobile Business Is Slowing, But Its AI Ambitions Aren’t
- Want to Own a Piece of Professional Sports? This ETF Could Be Your Ticket
- Welltower’s Strong Earnings Couldn’t Stop the Sell-Off—What’s Missing?
Receive News & Ratings for VanEck Biotech ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VanEck Biotech ETF and related companies with MarketBeat.com's FREE daily email newsletter.
